Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03092596 · ClinicalTrials.gov registry record · NA
Integrated Care (iCare) at Mount Sinai to Improve Substance Use Diagnosis and Treatment Practices in HIV Clinic Settings
A NA study of Substance Abuse, sponsored by Icahn School of Medicine at Mount Sinai.
- Completed
- Registry status
- NA
- Development phase
- 3,358
- Enrollment target
- 1
- Study location
NCT03092596: Completed NA study of Substance Abuse, sponsored by Icahn School of Medicine at Mount Sinai.
NCT03092596 is a NA study of Substance Abuse that has completed, run by Icahn School of Medicine at Mount Sinai. The registered enrollment target is 3,358 participants, below the 5,202-participant average among 58 other Substance Abuse trials with a reported enrollment target (35% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT03092596, a NA study of Substance Abuse, has completed, sponsored by Icahn School of Medicine at Mount Sinai.
- COMPLETED
- Registry status
- NA
- Development phase
- 3,358 participants
- Enrollment target
- 1
- Study location
Study Summary
Substance abuse and dependence is highly prevalent among people living with HIV and significantly exacerbates morbidity and mortality and accelerates HIV disease progression. Antiretroviral therapy (ART) has been the single most important treatment for slowing disease progression. ART adherence and HIV primary care are affected by a complex array of factors in the context of lives impacted by socioeconomic, psychological, and health challenges. Drugs and alcohol play a major role in non-adherence, engagement in care, and poor health outcomes among HIV-infected persons. While evidence is unequivocal that substance use treatment improves health outcomes, systems of care for the detection and treatment of substance abuse and dependence remain fragmented. Integrated approaches are key to the delivery of optimal care. Pragmatic or effectiveness trials can provide the best evidence about clinical practice to inform practitioners and policy makes about the most clinically and cost effective treatment to inform dissemination on a wider scale at the organizational and public health levels. The goal of this trial is to develop and test a comprehensive, integrated program to detect and reduce substance abuse and in turn, to improve ART adherence and HIV, substance use and associated health outcomes among HIV-infected patients. This trial will test the effectiveness of the intervention using a stepped wedge trial design to sequentially implement a screening tool and training of patient health navigators at HIV clinics in NYC.
Primary Outcome
Proportion of patients with an alcohol or drug use diagnosis at each HIV clinic compared to proportion of patients who enroll in substance use treatment
Conditions Studied
Interventions
- BEHAVIORAL Patient-administered screening tool
- BEHAVIORAL Patient health navigator-administered screening tool
- BEHAVIORAL Patient health navigator-assisted linkage to treatment
Study Locations (1)
New York
- Icahn School of Medicine at Mount Sinai - New York
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 3,358 participants |
| Start Date | 2017-02-02 |
| Est. Completion | 2020-06-30 |
| Phase | NA |
What the finished NCT03092596 record still lists
NCT03092596 is an interventional study that assigns participants to a tested intervention. Its 3,358 participants enrollment target places it among the larger protocols in the corpus, below the 5,202-participant average among 58 other Substance Abuse trials with a reported enrollment target (35% lower).
The record links to 1 condition, with Substance Abuse appearing as the primary indexed condition, and to 3 interventions - of which Patient-administered screening tool is the first listed.
NCT03092596 reports a single indexed study location in New York.
Frequently Asked Questions
What is clinical trial NCT03092596 about?
NCT03092596 is a clinical study titled "Integrated Care (iCare) at Mount Sinai to Improve Substance Use Diagnosis and Treatment Practices in HIV Clinic Settings". Substance abuse and dependence is highly prevalent among people living with HIV and significantly exacerbates morbidity and mortality and accelerates HIV disease progression. Antiretroviral therapy (ART) has been the single most important treatment for slowing disease progression. ART adherence and ...
What is the current status of trial NCT03092596?
This trial is currently completed. It is a NA study. The enrollment target is 3,358 participants. The study started on 2017-02-02. Estimated completion is 2020-06-30.
What conditions does trial NCT03092596 study?
This clinical trial studies the following conditions: Substance Abuse.
What interventions are being tested in trial NCT03092596?
The interventions under investigation include: Patient-administered screening tool (BEHAVIORAL), Patient health navigator-administered screening tool (BEHAVIORAL), Patient health navigator-assisted linkage to treatment (BEHAVIORAL).
Who is sponsoring clinical trial NCT03092596?
This trial is sponsored by Icahn School of Medicine at Mount Sinai, which has 708 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT03092596 being conducted?
This trial has 1 study location across New York. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Substance Abuse
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT03092596's enrollment target sits among peer trials
3,358 6th of 58 higher than 53 of 58 other Substance Abuse trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Substance Abuse trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Functional Connectivity Alterations in Suicidal Patients Among Opioid Users
RECRUITING · NA
-
Testing ALERT With GTO in Middle Schools
RECRUITING · NA
-
Testing Strategies to Improve Substance Misuse Prevention Research Use in State Policy Contexts
RECRUITING · NA
-
The STop UNhealthy Substance Use Now Trial
RECRUITING · NA
-
The Trans-Led Care Study
RECRUITING · NA
-
Data2Action Oregon Project: Supporting Data-driven Decision-Making for Substance Use Services, Policy, and Overdose Prevention
RECRUITING · NA
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT06880055 · 3,375 participants
Shield Post-Approval Study Protocol
- NCT03474029 · 3,400 participants · Phase 2
Assessment of the Safety, Tolerability, and Effectiveness of Rifapentine Given Daily for LTBI
- NCT07142954 · 3,400 participants · Phase 3
Epidemiology and Biomarker Study in Alzheimer's Disease
- NCT03674307 · 3,306 participants · NA
Screening for Asymptomatic Coronary Artery Disease in Kidney Transplant Candidates
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI